PMID: 11903415Mar 21, 2002Paper

Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients

Diabetes, Obesity & Metabolism
L S HermannL Ugander

Abstract

To assess the adjunct effect of metformin to insulin in type 2 diabetes. Obese and overweight type 2 diabetes patients treated with insulin for at least 1 year, and with poor glycaemic control (HbA1c > upper reference level + 2%), were included in a randomised, double-blind, placebo-controlled study. Patients were treated for 12 months with either metformin (850 mg b.i.d.) or placebo added to their usual insulin, which was stabilized during a 3-month placebo run-in period, but thereafter attempted to be unchanged. Thirty-seven patients were included. Two patients dropped out during run-in. There were no differences between the metformin (n = 16) and placebo (n = 19) group at baseline. Most patients received multiple insulin injections. Metabolic control was improved by addition of metformin. Mean change in HbA1c from baseline showed highly significant difference between groups at 3, 6, 9 and 12 months. Mean change (percentage units +/- s.d.) at 12 months was -1.1 +/- 0.7% vs. + 0.3 +/- 0.8% (p < 0.001) for HbA1c and -1.4 +/- 2.1 mmol/l vs. + 0.6 +/- 2.2 mmol/l (p = 0.025) for fasting blood glucose. Mean low density lipoprotein (LDL) cholesterol change differed slightly at 6 months, but not at 12 months. There were no changes in...Continue Reading

References

Nov 12, 1992·The New England Journal of Medicine·H Yki-JärvinenP Seppälä
Oct 1, 1985·Metabolism: Clinical and Experimental·H GinJ Aubertin
Mar 27, 1998·The New England Journal of Medicine·S E InzucchiG I Shulman
Jun 6, 1998·The British Journal of Psychiatry : the Journal of Mental Science·D J HallH Smith
Nov 20, 1998·Psychosomatics·M Binzer, G Kullgren
Jul 7, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·H C Howlett, C J Bailey
Oct 8, 1999·Diabetic Medicine : a Journal of the British Diabetic Association
Jul 15, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·L S Hermann

❮ Previous
Next ❯

Citations

Jul 27, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A Golay
Oct 13, 2005·Diabetes, Obesity & Metabolism·Suzanne M Strowig, Philip Raskin
Jan 30, 2009·Diabetes, Obesity & Metabolism·Mariëlle J P van Avendonk, Guy E H M Rutten
Jun 9, 2015·The Lancet. Diabetes & Endocrinology·Avivit CahnStefano Del Prato
Apr 22, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·I F DouekUNKNOWN Metformin Trial Group
Jun 12, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·R A DeFronzoM E Wintle
Oct 22, 2003·Primary Care·Jeanine Albu, Nazia Raja-Khan
Jul 21, 2004·Clinical Therapeutics·George Dailey
Apr 19, 2019·The Cochrane Database of Systematic Reviews·Kasper S MadsenBianca Hemmingsen
Aug 22, 2003·Drugs·Ripudaman S Hundal, Silvio E Inzucchi
Jul 17, 2018·International Journal of Endocrinology and Metabolism·Hengameh AbdiAtieh Amouzegar

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.